Search for a trial

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination
With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects with Extensive Stage Small Cell Lung
Cancer

This study has been transitioned to CTIS with ID 2024-511021-58-00 check the CTIS register for the current data. Primary Objective:- Number of participants with dose limiting toxicity - Number of participants with treatment-related adverse events -…

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab
in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of
Treatment (DeLLphi-301)

Primary (Parts 1 and 2)• To evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab Primary (Part 3)Evaluate safety of reduced mandatory monitoring…

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)

This study has been transitioned to CTIS with ID 2023-506541-39-00 check the CTIS register for the current data. Monotherapy (Parts A, B*, D, E, F and G)Primary Objectives - Evaluate the safety and tolerability of Tarlatamab - Part A only: Determine…